Mandate

Vinge advises AstraZeneca

January 30, 2013

Vinge has advised AstraZeneca in connection with the sale of its research facility in Södertälje to Acturum, a group formed by FAM, the Wallenber foundations’ management company, and PEAB. The transaction covers, among other things, real estate, laboratories, research projects and a significant number of laboratory equipment and is intended to create conditions for future research and enterprise within the entire filed of life science.

Vinge’s team consisted of responsible partner Malin Ohlin and associate Kristina Ekberg and also included partner Patrick Forslund and associates Daniel Unger, Johan Cederblad, Nazli Zia, Peter Alstergren, Claes Henriksson and project assistant Sara Andersson.

Related

Vinge advises Borgo in connection with its inaugural issuance of primary capital instruments (AT1)

Vinge has advised Borgo AB (publ) in connection with its successful issuance of primary capital instruments (so called “AT1 bonds”) in the amount of SEK 350 million with a floating rate coupon of 3-month STIBOR + 390 basis points.
January 29, 2026

Vinge advises J Bil in conjunction with the acquisition of Appelskog Bil AB

Vinge has advised the buyer J Bil AB in conjunction with the acquisition of all shares in Appelskog Bil AB.
January 29, 2026

Vinge has advised United Lithium Corp. in connection with the acquisition of Swedish Minerals AB

United Lithium is an exploration & development company focused on the global demand for lithium, uranium and rare earth elements.
January 29, 2026